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ABSTRACT  
Background: Information about the prevalence of adverse drug reactions (ADRs) 
among HIV infected and HIV uninfected patients receiving anti-tuberculous therapy 
in Africa is limited due to unavailability of local data or publications and hence the 
basis of this study. 
Objective: To determine the prevalence of adverse drug reactions among HIV infected 
and HIV uninfected adult patients on anti-TB therapy. 
Design: A retrospective cohort study. 
Setting: Kenyatta National Hospital, Kenya. 
Subjects: HIV infected and HIV uninfected patients receiving anti-TB therapy between 
January 2006 to December 2007
Main Outcome Measures:Documented adverse drug reactions. 
Results: Three hundred and fourteen records were reviewed, 157 for both HIV 
infected and HIV uninfected. Of the 314 patient files, 96 (30.5%) had ADRs; 70 
(44.6%) verses 26 (16.6%) for HIV infected and HIV uninfected respectively. Overall, 
the most frequent ADR among the two groups was gastrointestinal disturbances 
(21.7%) verses (10.2%) for HIV infected and uninfected respectively, (RR=2.44 
[1.28-4.63], P=0.006). This was followed by peripheral neuropathy (16.6%) verses 
(4.5%) for HIV infected and uninfected respectively, (RR=4.25 [1.79-10.12], P=0.005).  
73(46.49%) of the HIV infected patients were also receiving anti-retroviral therapy, of 
which 36(49.31 %) of them had ADRs documented. Twenty five (29.8%) of the HIV 
infected who were not taking anti-retroviral therapy, had ADRs documented. 
Conclusions: Gastrointestinal disturbances and peripheral neuropathy were the most 
common ADRs in both groups. Surveillance systems should be established in hospitals 
for ADRs monitoring and control. 
INTRODUCTION  
A review of literature shows that ADRs from 
first line anti- TB drugs occurs in both HIV 
infected and HIV uninfected patients (1). A 
retrospective study done in London, UK, revealed that 
serious adverse events (grade III and IV) were 
recorded in 40% HIV infected and 26% HIV 
uninfected individuals receiving anti-TB drugs. 
Peripheral neuropathy and persistent vomiting 
were more common in HIV-TB co-infected patients. 
The study further suggested that Africans might 
not experience ADRs at the same rate as their 
Caucasian counterparts (2). However, there is no 
evidence for this argument. 
 A retrospective study done in Germany on 
patients receiving first line anti-TB drugs reported 
that 23% of the patients’ treatment had to be 
interrupted because of ADRs. This study also 
reported that hepatotoxicity (11%), exanthema (6%) 
and arthralgia (2%) were the most frequent ADRs (2,3). 
In a retrospective study conducted in Canada 
among 430 patients treated for active TB, 1990 - 
1999, using first line TB therapy, 46 serious 
adverse reactions were reported. The incidence of 
serious side effects, especially hepatitis and 
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rash, was highest with pyrazinamide, and was 
associated with female sex, older age and birth 
in Asia and HIV infection. The consequences of 
these adverse events included hospitalisations, 
prolonged therapy, and more clinics and home 
visits (4,5). 
 One exploratory Ugandan study indicated that 
1% of HIV patients on anti-TB therapy developed 
hepatotoxicity and 0.8 % had elevated transaminase 
levels (4.5). All these studies did not estimate the 
Relative Risk (RR) of developing the ADRs
 Despite HIV and TB being prevalent in sub-
Saharan Africa, data on the prevalence of ADRs 
among African adult HIV infected and HIV 
uninfected patients taking anti-TB drugs was 
limited (6). This study aimed at determining the 
prevalence of ADRs in both HIV infected and 
uninfected African adults receiving ant-TB therapy 
and subsequently estimation of the Relative Risk of 
ADRs in these patients. 
MATERIALS AND METHODS  
Study approval was obtained from Kenyatta 
National Hospital (KNH) Ethics and Research 
committee. One hundred and fifty seven adult 
patients’ files of HIV infected and 157 HIV 
uninfected on anti-TB medications were sampled 
out of 806 patient files. All the file numbers for 
HIV-TB co-infected and HIV uninfected TB 
patients during the study period (January 2006 to 
December 2007) were retrieved and listed 
down for each month at the coding section 
of the hospital’s medical records department. 
 The files were then separated based on the 
inclusion criteria of the study, which were as 
follows. Firstly, all adult patient files for either 
HIV infected or HIV uninfected patients who were 
diagnosed with TB and started on anti-TB drugs 
between January 2006 and December 2007. The 
HIV status and the TB diagnosis were extracted from the 
patient notes as documented by the treating clinician. 
 Secondly, patient records with no other chronic 
infectious diseases or any other major illness for 
example, cardiovascular and renal. Third, the study 
considered patients records for first line TB treatment 
consisting of rifampicin, isoniazid, ethambutol, 
pyrazinamide and streptomycin. Last, only complete 
patient files were included in this study. 
 The exclusion criteria were as follows; First, 
Patients less than 18 years on the day of TB diagnosis. 
Secondly, all patients whose HIV status was not 
documented were excluded from the study. Third, 
all the patients who had other co-existing chronic 
infectious diseases or any other major illness 
for example, cardiovascular and renal. Fourth, 
incomplete patient files with missing pages resulting 
in loss of information. Last, patient files whose 
records documented anti-TB treatment duration of 
less than seven days of starting intensive phase of 
TB treatment. 
 Simple random sampling was used to pick the 
files for the study. At least seven patient files were 
randomly picked for each month for both groups. 
If a given month had less than seven patient files 
meeting the inclusion criteria for either of the two 
groups, then all these files were included in the 
study. The remaining monthly quota was filled by 
uniformly increasing the number of files sampled in 
the remaining months of the year(s) of study. 
 An adverse drug reaction (ADR) was defined 
according to the World Health Organization (WHO) 
as ‘Any noxious or unintended response to a drug, 
which occurs at doses normally used in humans for 
the prophylaxis, diagnosis or treatment of disease or 
for the modification of physiological function (3). 
 In this study ADRs considered were peripheral 
neuropathy, hepatotoxicity, ocular toxicity, 
gastrointestinal disturbances, cutaneous reactions 
and ototoxicity. These ADRs were extracted from 
the patients’ records as documented by the treating 
clinician. These ADRs then formed our dependent 
variables. The independent variables considered 
in this study were age of the HIV infected and HIV 
uninfected patients, anti-TB drugs, anti-retrovirals, 
gender, education levels, occupation and marital 
status. 
 Data quality was assured by using complete files 
in the study. After data collection were completed, 
ten (6 %) patient files for each of the groups were 
reviewed by a co-investigator in five order to compare 
with the data collected by the principal investigator. 
The data were then keyed into computer database 
using Microsoft Access package (MS Access). When 
data entry was completed, data clean up was done by 
checking the data entered into the computer database 
against data recorded in the data collection forms. 
Any errors identified during data clean up were 
corrected. The data were analysed using the SPSS® 
version 13.0 software. Descriptive statistics, frequency 
and percentage proportions were determined. Tables 
and figures were presented for important findings 
Statistical significance was determined using the 
Pearson Chi -square at p<0.05, at 95% confidence level. 
Continuous variables were compared using t-tests. 
RESULTS 
 
Records 314 patients were reviewed of which 
157 were HIV infected and 157 HIV uninfected. 
There was no significant difference in the mean 
ages for two study groups, (36.7 vs. 35.7) for 
the HIV infected and uninfected respectively. 
A total of 83 and 28 ADRs were recorded among 
HIV infected and HIV uninfected adult patients 
taking anti-TB drugs, respectively. ADRs were more 
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common in HIV infected patients 70 (44.6%) compared 
to HIV uninfected patients 26 (16.6%), (RR = 2.692 
[1.819 - 3.985], P < 0.001). More HIV infected than HIV 
uninfected patients had more than one ADR; 11(7%) 
versus 2 (1.3%) respectively. (RR=5.50 [1.239 -24.412], 
p=0.02). Seventy three (46.49%) of the HIV infected 
patients taking anti-TB drugs were also receiving 
anti-retroviral therapy, of which 37(50.7%) of them 
had ADRs documented. Twenty five (29.8%) of the 
HIV infected who were not taking anti-retroviral 
therapy, had ADRs documented. 
Table 1
Prevalence of specific ADRs among the study subjects
  HIV status 
 HIV Positive  HIV Negative  p value  Relative Risks with 
Specific ADRs     corresponding 
 N = 157 N= 157       confidence  
 n (%) n(%)  intervals   
GIT disturbances    34(21.7%)    16(10.2%)    0.006    2.44(1.28-4.63) 
Peripheral neuropathy    26(16.6%)    7(4.5%)    0.005    4.25(1.79-10.12) 
Cutaneous reactions    10(6.4%)    2(1.3%)    0.02    5.27(1.14-24.47) 
Hepatotoxicity    9(5.7%)    2(1.3%)    0.03    4.71(1.23-22.17)   
Ocular toxicity    3(1.9%)    1(0.6%)    0.3    3.03(0.313-29.54) 
Ototoxicity    1(0.6%)    0(0%)    0.3    -       
DISCUSSION  
Our study revealed that adult HIV infected 
patients receiving anti-TB were at least two times 
(RR=2.692 [1.819-3.985]) more likely to develop 
ADRs than their HIV uninfected counterparts 
having the same treatment. This was in line with 
previously study that have reported ADRs of 
anti-TB drugs were comparatively more frequent 
in the HIV infected patients taking anti-TB drugs 
(1,7). There are few comparative studies on 
ADRs among HIV infected and HIV uninfected 
adult patients taking anti- TB drugs. Furthermore, 
the few studies done reported only the prevalence 
rates of ADRs and not the RR (1,2,6,8,9) of developing 
the ADRs. Consequently, this study calculated the 
RR for specific ADRs to show the likelihood of the 
patients in the two groups of developing the ADRs. 
In our study 50.7% of the HIV infected patients on 
anti-TB therapy and anti-retroviral therapy (ARvs), 
documented ADRs compared to 29.8% of the HIV 
infected patients on anti-TB therapy but not on 
anti-retroviral therapy. This was in agreement 
with previous studies that have reported increased 
Gastrointestinal disturbances and peripheral neuropathy were the most common ADRs encountered. These 
were more prevalent in HIV infected than HIV uninfected patients. 
Table 2
Prevalence of ADRs and interventions undertaken in the study groups 
Specific Adverse drug  HIV infected HIV uninfected Interventions 
reaction        N = 157)    N = 157)       
 n (%)    n (%)
A. Hepatotoxicity      9 (5.7 %)    2(1.3%)  Anti-TB 
   medication,  
   ARVs stopped 
B. Peripheral neuropathy      26 (16.6%)    7 (4.5%)    Pyridoxine 
C. Ocular toxicity      3 (1.9%)    1(0.3%)    Referral for
   ophthalmological 
   review  
D. Gastrointestinal      34 (21.7%)    16 (10.2%)    Loperamide, 
disturbances   Metoclopamide,
   Intravenous fluids. 
E. Cutaneous reactions      10 (6.4%)    2 (1.3%)    Anti- TB stopped 
F. Ototoxicity      1(0.6%)    0          Streptomycin stopped. 
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prevalence of ADRs in patients receiving anti-retroviral 
therapy (11). Consequently, patients co-infected 
with HIV and TB should be monitored for ADRs. 
 HIV infected patients taking anti-TB drugs 
were at least four times (RR= 4.71 [1.23-22.17]) 
more likely to develop hepatotoxicity than their 
HIV uninfected counterparts. A retrospective 
study done by Breen et al., reported no difference 
in the prevalence of hepatotoxicity among HIV 
infected and HIV uninfected adult patients 
taking anti-TB drugs (2). The difference in 
study results may reflect the difference in study 
criteria, as Breen et al.,  only considered grade III and 
IV ADRs. In our study the treating clinicians did not 
grade the ADRs in the patient notes. The confidence 
interval from our findings is large; therefore, more 
prospective studies are needed to confirm the RR for 
developing hepatotoxicity. 
 Peripheral neuropathy was at least four times 
more likely to develop in adult HIV infected patients 
receiving anti-TB drugs than their HIV uninfected 
counterparts (RR= 4.25[1.79-10.12]). This was in 
agreement with other previous studies which also 
suggested that HIV infected patients were more 
prone to developing isoniazid-induced peripheral 
neuropathy (2,7,11). Although a number of risk 
factors for isoniazid induced peripheral neuropathy 
have been reported elsewhere (2,12) including the 
poorly nourished, extent of disease, alcoholics, 
diabetics, uraemic patients and pregnancy, our study 
had a low proportion of alcohol use and pregnant 
women thus making assessment of these risk factors 
unfeasible. Gastrointestinal disturbances were the 
most commonly recorded ADR in both the study 
groups. Our study findings revealed that adult 
HIV infected patients taking anti-TB drugs were at 
least two times (RR= 2.44 [1.28-4.63]) more likely to 
develop gastrointestinal disturbances than their HIV 
uninfected counterparts. Nevertheless, it should be 
noted that this study was unable to assign all cases 
of this condition to anti-TB drugs, as other likely 
causes of gastrointestinal disturbances were not 
investigated in this study. Furthermore, in this study 
62% of the HIV infected patients who developed this 
condition were also taking ARVs, a possible cause of 
gastrointestinal disturbances. 
 Our findings suggested that adult HIV infected 
patients taking anti-TB drugs were at least five 
times (RR=5.27 [1.14-24.47]) more likely to develop 
cutaneous reactions than their HIV uninfected 
counterparts. All anti-TBs and majority ARvs have 
been reported to cause a skin rash (13). Consequently, 
where anti-TB and ARvs were given together, it was 
difficult to pinpoint a particular drug as the cause 
of cutaneous drug reaction. The confidence interval 
from our findings is large; therefore, further studies 
are needed in this area. 
 It is well documented that ocular toxicity 
is uncommon (7,12,14,15). However, data on 
comparative studies on ocular toxicity among HIV 
infected and HIV uninfected adult patients taking 
anti-TB drugs are limited. Although, our study 
reported no difference in RR for developing ocular 
toxicity between the two groups: these findings 
should be interpreted with caution, further studies 
are needed in this area. 
 Only one HIV infected patient developed 
ototoxicity. This was in line with previous studies 
(16) that have reported ototoxicity to be uncommon. 
In our study, only a small proportion of our study 
patients were on the streptomycin containing 
regimen. Therefore, it was impossible to assess risk 
estimate for developing ototoxicity between the 
two groups. Consequently, any conclusions based 
on one rare case might be misleading and, therefore 
more large sample-sized studies are required 
to establish RR of ototoxicity in similar cohort. 
 It is important to note that the rates of under 
reporting in the files might have been similar 
regardless of the HIV status. Furthermore, these 
findings might not represent the RR estimate of 
developing ADRs among HIV infected and HIV 
uninfected children taking anti-TB drugs. 
In conclusion, ADRs were more likely to occur 
in HIV infected African adults taking anti-TB 
therapy than their HIV uninfected counterparts. 
Gastrointestinal disturbances and peripheral 
neuropathy were the most common ADRs among 
both the two groups. Adverse drug reaction 
surveillance systems should be established in 
hospitals. Prospective studies are needed in the future. 
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